Conflict of interest statement: Competing interests: None declared.52. Nanomedicine. 2018 Jul;14(5):1733-1742. doi: 10.1016/j.nano.2018.04.019. Epub2018 May 3.Multimodal doxorubicin loaded magnetic nanoparticles for VEGF targetedtheranostics of breast cancer.Semkina AS(1), Abakumov MA(2), Skorikov AS(3), Abakumova TO(4), Melnikov PA(5),Grinenko NF(5), Cherepanov SA(6), Vishnevskiy DA(7), Naumenko VA(8), IonovaKP(5), Majouga AG(9), Chekhonin VP(6).Author information: (1)Pirogov Russian National Research Medical University, Moscow, RussianFederation; The National University of Science and Technology MISiS, Moscow,Russian Federation.(2)Pirogov Russian National Research Medical University, Moscow, RussianFederation; The National University of Science and Technology MISiS, Moscow,Russian Federation. Electronic address: abakumov1988@gmail.com.(3)Lomonosov Moscow State University, Moscow, Russian Federation.(4)Skolkovo Institute of Science and Technology, Moscow, Russian Federation.(5)Serbsky National Medical Research Center for Psychiatry and Narcology, Moscow,Russian Federation.(6)Pirogov Russian National Research Medical University, Moscow, RussianFederation; Serbsky National Medical Research Center for Psychiatry andNarcology, Moscow, Russian Federation.(7)Pirogov Russian National Research Medical University, Moscow, RussianFederation.(8)The National University of Science and Technology MISiS, Moscow, RussianFederation.(9)The National University of Science and Technology MISiS, Moscow, RussianFederation; Lomonosov Moscow State University, Moscow, Russian Federation; DmitryMendeleev University of Chemical Technology of Russia, Moscow, RussianFederation.In presented paper we have developed new system for cancer theranostics based on vascular endothelial growth factor (VEGF) targeted magnetic nanoparticles.Conjugation of anti-VEGF antibodies with bovine serum albumin coated PEGylatedmagnetic nanoparticles allows for improved binding with murine breastadenocarcinoma 4T1 cell line and facilitates doxorubicin delivery to tumor cells.It was shown that intravenous injection of doxorubicin loaded VEGF targetednanoparticles increases median survival rate of mice bearing 4T1 tumors up to50%. On the other hand magnetic resonance imaging (MRI) of 4T1 tumors 24 h after intravenous injection showed accumulation of nanoparticles in tumors, thusallowing simultaneous cancer therapy and diagnostics.Copyright Â© 2018 Elsevier Inc. All rights reserved.DOI: 10.1016/j.nano.2018.04.019 PMID: 29730399 